Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
NEWARK, Calif., Aug. 28, 2017 -- Depomed Inc. (NASDAQ:DEPO) today announced that it has been selected to join the Collaborative for Effective Prescription Opioid Policies (CEPOP) a diverse group of over 70 stakeholders creating and advancing policies and educational initiatives aimed at reducing opioid abuse and promoting treatment options for those living with pain or confronting addiction.
“We are pleased to be joining a well-respected organization that shares our commitment to reducing prescription opioid misuse as well as highlighting the ethical and responsible prescribing and use of treatment options for those living with pain,” said Arthur Higgins, President and Chief Executive Officer of Depomed. “We look forward to engaging with this unique group of patient, family advocacy, public health, prescriber, research and supply chain organizations to develop and implement strategies to address responsible opioid use while recognizing the needs of patients in pain. At Depomed, it is clear to us that tackling these issues requires collaboration among all stakeholders, and we view this partnership with CEPOP as an important addition to our ongoing and future activities aimed at highlighting the responsible prescribing and use of opioids.”
About the Collaborative for Effective Prescription Opioid Policies (CEPOP)
Launched in January of 2015, the Collaborative for Effective Prescription Opioid Policies (CEPOP) brings together a broad array of stakeholders interested in reducing opioid medication abuse, misuse, and diversion. Specifically, CEPOP supports a comprehensive and balanced public policy agenda that reduces abuse and promotes treatment options, both for those living with pain and confronting addiction. CEPOP’s advocacy is focused on driving actions in the public sector that develop and deploy evidence-based solutions to these challenges. For more information visit https://cepoponline.org/
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
